DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) Receives $12.33 Consensus Price Target from Analysts

DiaMedica Therapeutics, Inc. (NASDAQ:DMAC) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $12.3333.

Several research firms have recently commented on DMAC. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Monday, April 20th. Wall Street Zen lowered DiaMedica Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 9th.

Institutional Trading of DiaMedica Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the business. Strs Ohio lifted its position in DiaMedica Therapeutics by 19.7% in the third quarter. Strs Ohio now owns 9,100 shares of the company’s stock valued at $63,000 after buying an additional 1,500 shares during the last quarter. World Investment Advisors lifted its position in DiaMedica Therapeutics by 7.7% in the fourth quarter. World Investment Advisors now owns 36,975 shares of the company’s stock valued at $294,000 after buying an additional 2,650 shares during the last quarter. Rhumbline Advisers lifted its position in DiaMedica Therapeutics by 14.5% in the third quarter. Rhumbline Advisers now owns 27,357 shares of the company’s stock valued at $188,000 after buying an additional 3,463 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new position in DiaMedica Therapeutics in the fourth quarter valued at about $29,000. Finally, BNP Paribas Financial Markets lifted its position in DiaMedica Therapeutics by 24.4% in the second quarter. BNP Paribas Financial Markets now owns 18,882 shares of the company’s stock valued at $74,000 after buying an additional 3,709 shares during the last quarter. 10.12% of the stock is owned by institutional investors and hedge funds.

DiaMedica Therapeutics Price Performance

NASDAQ DMAC opened at $5.91 on Monday. DiaMedica Therapeutics has a 52 week low of $3.47 and a 52 week high of $10.42. The business’s fifty day simple moving average is $6.48 and its 200-day simple moving average is $7.50. The firm has a market cap of $318.43 million, a PE ratio of -8.32 and a beta of 0.99.

DiaMedica Therapeutics (NASDAQ:DMAC) last posted its quarterly earnings results on Wednesday, May 6th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.02). Research analysts expect that DiaMedica Therapeutics will post -0.86 EPS for the current year.

About DiaMedica Therapeutics

DiaMedica Therapeutics, Inc (NASDAQ: DMAC) is a clinical?stage biopharmaceutical company focused on developing novel therapies for acute and chronic central nervous system conditions. The company’s lead product candidate, DM199, is a recombinant form of human tissue kallikrein-1 designed to promote neuroprotection and tissue repair through modulation of the kallikrein?kinin system. DiaMedica’s research and development efforts are centered on translating the regenerative potential of DM199 into effective treatments for disorders with high unmet medical need.

DM199 is being evaluated in acute ischemic stroke, where preclinical studies have demonstrated potential benefits in blood flow restoration, inflammation reduction and neuronal survival.